Branched Chain Amino Acid Enriched Solutions in the Treatment of Hepatic Encephalopathy: A Controlled Trial

1984 ◽  
pp. 323-333 ◽  
Author(s):  
F. Fiaccadori ◽  
F. Ghinelli ◽  
G. Pedretti ◽  
G. Pelosi ◽  
D. Sacchini ◽  
...  
Keyword(s):  
Hepatic Encephalopathy ◽  
Amino Acid ◽  
Controlled Trial ◽  
Branched Chain Amino Acid ◽  
Branched Chain

Prophylaxis of Hepatic Encephalopathy after Porta-Caval Anastomosis using Branched Chain Amino Acid Mixtures

1984 ◽  
pp. 345-350 ◽  
Author(s):  
A. Puglionisi ◽  
F. Ceriati ◽  
I. R. Marino ◽  
C. Cavicchioni ◽  
G. De Luca ◽  
...  
Keyword(s):  
Hepatic Encephalopathy ◽  
Amino Acid ◽  
Branched Chain Amino Acid ◽  
Amino Acid Mixtures ◽  
Branched Chain

scholarly journals CORELLATION BRANCHED CHAIN AMINO ACID IN INHIBITING THE PROGRESSIVITY OF CHRONIC KIDNEY DISEASE STAGE 2-4 IN CHILDREN

2019 ◽  
Vol 26 (2) ◽  
Author(s):  
Esthy Poespitaningtyas ◽  
Roedi Irawan ◽  
Ninik Asmaningsih Soemyarso ◽  
Jusak Nugraha
Keyword(s):  
Chronic Kidney Disease ◽  
Amino Acid ◽  
Kidney Disease ◽  
Nutritional Status ◽  
Controlled Trial ◽  
Chronic Kidney Disease Stage ◽  
Disease Stage ◽  
Branched Chain Amino Acid ◽  
Ckd Stage ◽  
Branched Chain

Chronic kidney disease (CKD) is not uncommon issue in children. CKD is the abnormality of structure or function of the kidney that occurs for more than 3 months. Progresivity of CKD characterized by the presence of longitudinal decline in Glomerulus Filtration Rate (GFR), proteinuria and hypertension. One of the recommendations of the prevention of nutritional supplementation in CKD by administering oral Branched Chain Amino Acid (BCAA). Recently, there has been no research to figure the effects of the of BCAA on children with CKD stage 2-4. Randomized pre-post test controlled trial study was conducted in Nephrology pediatric outpatient clinic Dr. Soetomo hospital with CKD stage 2-4, divided into 2 groups, the BCAA and placebo, followed for 8 weeks to be evaluated for GFR, albumin, proteinuria, blood pressure and nutritional status. Sixteen children with CKD stage 2-4 were enrolled in this study, 71.4% of patients were boys. The mean age was 12.5 (SD 2.90) years. CKD stage 2 about 50% (p=0,767). Nephrotic syndrome was the most common underlying cause of CKD (p=0,149). Moderate malnutrition was about 50% (p=1,000) and short stature was 64.28% (p=1.000). In BCAA group there was decrease of GFR -5.08±7,13 (p=0.055), increase of albumin serum 0.20±0.23 (p=0,062), decrease of delta systole -11,57±15.08 (p=0,565) and diastole -4,85±16.25 (p=0,708), weight loss -0.07±1.01 (p=0.828), an increase of height 0.14±0.24 (p=0,771), and a decrease in BMI -0.03±0.74 (p=0,389). The conclusion in this study is Branched chain amino acid (Leucine, Isoleucine and Valine) supplementation did not provide significant effect in inhibiting progresivity of CKD stage 2-4 in children and improvement of nutritional status.

Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy

1990 ◽  
Vol 11 (1) ◽  
pp. 92-101 ◽  
Author(s):  
G Marchesini ◽  
F.S Dioguardi ◽  
G.P Bianchi ◽  
M Zoli ◽  
G Bellati ◽  
...  
Keyword(s):  
Hepatic Encephalopathy ◽  
Amino Acid ◽  
Acid Treatment ◽  
Chronic Hepatic Encephalopathy ◽  
Branched Chain Amino Acid ◽  
Branched Chain

scholarly journals Branched-Chain Amino Acid Supplementation during a 100-km Ultra-Marathon^|^mdash;A Randomized Controlled Trial

2012 ◽  
Vol 58 (1) ◽  
pp. 36-44 ◽  
Author(s):  
Beat KNECHTLE ◽  
Claudia MRAZEK ◽  
Andrea WIRTH ◽  
Patrizia KNECHTLE ◽  
Christoph Alexander R^|^Uuml;ST ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Amino Acid ◽  
Controlled Trial ◽  
Amino Acid Supplementation ◽  
Acid Supplementation ◽  
Randomized Controlled ◽  
Branched Chain Amino Acid ◽  
Branched Chain
Sign in / Sign up

Export Citation Format

Share Document